Comparing ascitic aspirate and tissue biopsy in the diagnosis of ovarian malignancy

References

• Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. 2002. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 40:237–244.
   PubMed Web of Science ®Google Scholar
• Cancer Research UK. 2010. How common is ovarian cancer? Available at: http://info.cancerresearchuk.org/cancerstats/types/ovary/incidence/index.htm#source1
   Google Scholar
• Cherchi PL, Marras V, Capobianco G, Ambrosini G, Piga M, Fadda GM . 2001. Immunohistochemical evaluation of a new epithelial antigen, Ber-EP4, in ovarian cancer: preliminary results. European Journal of Gynaecological Oncology 22:433–435.
   PubMed Web of Science ®Google Scholar
• Chu P, Wu E, Weiss LM. 2000. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Modern Pathology 13:962–972.
   PubMed Web of Science ®Google Scholar
• Comin CE, Saieva C, Messerini L. 2007. H-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immu-nohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. American Journal of Surgical Pathology 31:1139–1148.
   PubMed Web of Science ®Google Scholar
• Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I . 2005. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clinical Cancer Research 11:3766–3772.
   PubMed Web of Science ®Google Scholar
• Hecht JL, Pinkus JL, Weinstein LJ, Pinkus GS. 2001. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. American Journal of Clinical Pathology 116:483–488.
   PubMed Web of Science ®Google Scholar
• Hewitt MJ, Hall GD, Wilkinson N, Perren TJ, Lane G, Spencer JA. 2006. Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis. International Journal of Gynecological Cancer 16(Suppl 1):108–110.
   PubMedGoogle Scholar
• Jang KY, Kang MJ, Lee DG, Chung MJ. 2001. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Analytical and Quantitative Cytology and Histology 23:400–404.
   PubMedGoogle Scholar
• Kaufmann O, Deidesheimer T, Muehlenberg M, Deicke P, Dietel M. 1996. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology 29:233–240.
   PubMed Web of Science ®Google Scholar
• Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ. 1999. Immunohistochemical differentiation between primary adenocar-cinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. Journal of Clinical Pathology 52:283–290.
   PubMed Web of Science ®Google Scholar
• Mottolese M, Venturo I, Donnorso RP, Curcio CG, Rinaldi M, Natali PG. 1988. Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin. European Journal of Cancer and Clinical Oncology 24: 1277–1284.
   PubMedGoogle Scholar
• Mottolese M, Cianciulli A, Venturo I, Perrone Donnorso R, Salzano M, Benevolo M . 1992. Selected monoclonal antibodies can increase the accuracy of cytodiagnosis of neoplastic effusions of cryptic origin expanded in a short term culture. Diagnostic Cytopathology 8:153–160.
   PubMed Web of Science ®Google Scholar
• Ordóñez NG. 1998. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. American Journal of Surgical Pathology 22:1203–1214.
   PubMed Web of Science ®Google Scholar
• Ordóñez NG. 2006. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Modern Pathology 19: 34–48.
   PubMed Web of Science ®Google Scholar
• Park SY, Kim BH, Kim JH, Lee S, Kang GH. 2007. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Archives of Pathology and Laboratory Medicine 131: 1561–1567.
   PubMed Web of Science ®Google Scholar
• Pomjanski N, Grote HJ, Doganay P, Schmiemann V, Buckstegge B, Bocking A. 2005. Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Diagnostic Cyto-pathology 33:309–315.
   PubMed Web of Science ®Google Scholar
• Roh MS, Hong SH. 2002. Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes. Journal of Korean Medical Science 17:512–517.
   PubMed Web of Science ®Google Scholar
• Rothacker D, Mobius G. 1995. Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: a thirty-year autopsy study. International Journal of Gynecological Pathology 14:310–318.
   PubMed Web of Science ®Google Scholar
• Shinozuka T, Ebisawa K, Miyamoto T, Murakami M, Fujii A, Osamura Y. 1991. Application of immunocytochemistry to the cytologic study of peritoneal fluids in patients with ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 43:1355–1362.
   PubMedGoogle Scholar
• Spencer JA, Swift SE, Wilkinson N, Boon AP, Lane G, Perren TJ. 2001. Peritoneal carcinomatosis: image-guided peritoneal core biopsy for tumor type and patient care. Radiology 221:173–177.
   PubMed Web of Science ®Google Scholar
• Tot T. 2002. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. European Journal of Cancer 38:758–763.
   PubMed Web of Science ®Google Scholar
• Zhu W, Michael CW. 2007. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagnostic Cyto-pathology 35: 370–375.
   PubMed Web of Science ®Google Scholar